NCT07747948Not yet recruiting
Population Pharmacokinetics of Apixaban in Asian Patients With Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 5 Aug 2026
Brief summary (registry, in English)
The goal of this observational study is to learn about the variability of apixaban blood levels and identify the clinical factors that influence them in Asian patients with atrial fibrillation. The main questions it aims to answer are: 1. What are the specific pharmacokinetic parameters and their variabilities for apixaban in this patient population? 2. Which clinical factors, such as kidney function or body weight, are the primary predictors of how apixaban is cleared and distributed in the body? Participants will be asked to give consent to allow researchers to use their existing electronic outpatient medical records and previously collected blood concentration data for analysis.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 11 May 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Chulalongkorn University
- Diseases
- Atrial fibrillation
- NCT number
- NCT07747948
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Sept 2026 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with end-stage renal disease (ESRD) receiving renal replacement therapy
- Patients with a history of acute kidney injury (AKI) within 3 months prior to study enrollment
- Patients receiving moderate to strong inhibitors or inducers of CYP3A4 or P-glycoprotein (P-gp), such as ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir, naproxen, clarithromycin, rifampicin, phenytoin, carbamazepine, phenobarbital, and St. John's Wort (Patients receiving amiodarone, verapamil, or diltiazem are not excluded and will be included for covariate analysis)
Other illness
- Patients with gastrointestinal disorders that significantly affect drug absorption, such as short bowel syndrome
Other
- Patients with cirrhosis of Child-Pugh class C severity
Who the study is looking for
- Age 18 years and older
- Patients diagnosed with atrial fibrillation
- Receiving apixaban at a fixed dose of 2.5 mg or 5 mg twice daily for at least 3 consecutive days
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine, Chulalongkorn University Coordinator of this site? Confirm its status | Pathum Wan | Thailand | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.